This study tests a medicine called Seladelpar for people with a liver illness named Primary Biliary Cholangitis (PBC) and mild liver damage, known as compensated cirrhosis. To join, you need to be 18 or older, have PBC, and show signs of cirrhosis. Cirrhosis is when the liver is scarred but still works. The study excludes people with severe liver issues or those who've had liver transplants.

• Duration and Visits: Participation involves following instructions for taking the study drug and completing a schedule of assessments.
• Eligibility: You can't join if you've been exposed to Seladelpar before, have severe liver conditions, or are on a liver transplant list.
• Safety: Female participants need to use specific birth control methods, and males with partners who can become pregnant must use barrier contraception.

Participants will help researchers understand if Seladelpar can improve health outcomes for people with PBC and compensated cirrhosis. The study carefully checks eligibility and requires participants to follow study rules to ensure safety.